After keeping quiet on the M&A front since its failed hostile bid for Allergan, serial acquirer Valeant last week announced its leading bid for the bankrupt Dendreon's assets. Now, it may be ready to strike again.
The Medicines Company bought out the shares of Annovation Biopharma it didn't already own, getting exclusive rights to a new anesthetic and scooping up a tiny biotech incubated by Atlas Venture.
Analysts have identified an area of European biopharma in which 2014 was a middling year: M&A. The data show that while deals involving U.S. biotechs hit new highs, the renewed optimism in Europe has yet to translate into the signing of checks.
Wright Medical Group had expected to complete its acquisition of Tornier during the first half of this year. But now that is a "best case scenario," according to a statement from the company. The Federal Trade Commission has extended the waiting period until the deal close in order to give Tornier time to deal with the agency's concerns about its lower extremity products.
Wound-care outfit Alliqua Medical shelled out $30.4 million for ultrasound therapy company Celleration, broadening its portfolio and gaining ground in regenerative medicine.
Secretary of Health and Human Services Sylvia Burwell, incoming head of the federal Centers for Medicare & Medicaid Services, last week set explicit goals toward paying providers based on quality and not quantity, as the agency aims to put the fee-for-service model to sleep--permanently.
With Covidien deal in the bag, Omar Ishrak urges Medtronic employees to stay focused on the company mission
In the wake of the closure of Medtronic's mega, nearly $50 billion purchase of Covidien, CEO Omar Ishrak announced that the company will give $10 to charity for every email he receives from an employee containing reflections on the company's mission to restore health, alleviate pain and extend life.
Fast-expanding CRO genae is buying into clinical trial technology, acquiring a company that focuses on electronic data capture.
Mylan will pay $750 million in cash to buy the women's healthcare businesses from India's Famy Care, placing it as the top seller of contraceptives in emerging markets.
Ranbaxy-Sun U.S. approval hinges on selling antibacterial drug as FTC notes reach of Indian generic giant
Ranbaxy Laboratories may soon be selling its generic minocycline antibacterial drug to Torrent Pharmaceuticals as a condition for U.S. approval for its merger with Sun Pharmaceuticals.